harrison.ai, Sonic Healthcare Launch Pathology AI Joint Venture
Healthcare AI startup harrison.ai and ASX-listed diagnostic provider Sonic Healthcare have set up a joint venture called franklin.ai.
Based on a media release, franklin.ai will improve the accuracy and efficiency of diagnosis with AI-powered assistive devices to pathologists.
The initiative will be led by Stephen Raffles, former CEO of harrison.ai. As CEO, he will oversee a team of more than 70 specialist engineers, data scientists and clinical experts by the end of 2023.
Other key recruits for the joint venture include former racemed director Peter Dassos, general manager and head of talent Celeste Kokabe, who was previously with Atlasian and Investibal.
“We’ve spent months building the right team to work hand-in-hand with pathologists to develop AI-powered tools that will enhance their key role at the heart of the healthcare system,” Raffles said.
annalize.ai makes the original appointment before entering the US
AI radiology provider annalize.ai has made two key appointments to support its planned expansion into the U.S. market.
In a press statement, the company announced that it has named Lakshmi Gudapakkam as CEO and Dr Rick Abramson as CMO. Both newly appointed executives are expected to help accelerate the global expansion of annalize.ai and secure further partnerships with healthcare providers, technology developers and regulators around the world.
Gudapakkam previously served as VP of US-based Quest Diagnostics and general manager of the US Eastern Region. He has been a senior global technology and business leader in GE Healthcare and Philips Healthcare for more than two decades.
Meanwhile, Dr. Abramson, an American physician and board-certified radiologist, was the former corporate VP of the radiology services at HCA Healthcare.
Their appointments also come as annalize.ai received 510 (k) clearance for the US Food and Drug Administration’s flagship product analysis enterprise CXR in March. The AI Book X-ray tool has also been cleared for use in Australia, the United Kingdom, Europe, Southeast Asia and New Zealand.
ResApp has extended the license agreement with Medgate
ASX-listed digital health firm ResApp Health has extended a commercial license agreement with telemedicine provider Medgate to use diagnostic testing of its smartphone-based respirators.
The companies entered into a licensing agreement in August last year to use ResAppDx on the Medgate telehealth platform. The app-based test uses machine learning to analyze cough sounds and diagnose respiratory diseases.
According to a corporate disclosure, the extension has been granted for another 12 months.
Dr Andy Fisher, CEO of Medgate, shared that over the past year, they have found more evidence of the benefits of ResAppDx for their physicians and patients. “We look forward to expanding the use of ResAppDx to further realize these benefits for our patients,” he added.
Medgate intends to expand the use of ResAppDx throughout its “additional patient journey” in its telemedicine services and to bring the technology to its platform in Germany in 2023.
Volpara will deploy its AI breast imaging solution at RadNet’s diagnostic centers
Volpara Health Technologies, a New Zealand-based health technology developer, has signed a use agreement with RadNet, an imaging service provider in the United States.
Set for an initial period of 42 months, their contract is to install Volpara Analytics and Volpara Risk Pathways software across RadNet’s 353 imaging centers in seven U.S. states.
Volpara Analytics manages the quality of mammography while Volpara Risk Pathway provides screening for patients at high risk of breast cancer.
According to a company release, implementation is set for next year.